|Elimination half-life||0.81 hours|
|Chemical and physical data|
|Molar mass||332.243 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Fospropofol (INN), often used as the disodium salt (trade name Lusedra) is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
Several water-soluble derivatives and prodrugs of the widely used intravenous anesthetic agent propofol have been developed, of which fospropofol has been found to be the most suitable for clinical development thus far. Purported advantages of this water-soluble chemical compound include less pain at the site of intravenous administration, less potential for hyperlipidemia with long-term administration, and less chance for bacteremia. Often, fospropofol is administered in conjunction with an opioid such as fentanyl.
Initial trial results on fospropofol pharmacokinetics were retracted by the investigators. As of 2011, new results were not available.